Streetbeat News

Products Services

BIIB

Biogen has received marketing authorization from the European Commission for QALSODY, a treatment for SOD1-ALS, a rare and fatal genetic form of ALS. This is Biogen's third rare disease therapy approved in the EU, highlighting their commitment to addressing high unmet medical needs.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 8:52 pm

OCX

Oncocyte Corporation (NASDAQ:OCX) announced favorable data for its lead product VitaGraft Kidney, published in the New England Journal of Medicine. The data, presented at the American Transplant Congress, show potential for monitoring therapeutic efficacy and recurrence in kidney transplants.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 8:50 pm

TMUS

Whales have shown a bullish stance on T-Mobile US (NASDAQ:TMUS) with significant options trading activity. Out of 28 trades, 25 were calls and 3 were puts, indicating a strong bullish sentiment. The price range targeted by these trades is between $135.0 and $195.0. Currently, TMUS is trading at $170.7, up by 1.08%, with an RSI suggesting it may be approaching overbought territory. The consensus target price is $200.0.

Portfolio Pulse from Benzinga Insights

May 30, 2024 | 8:46 pm

GILD

Gilead shares are trading lower after the company's Phase 3 TROPiCS-04 study missed its primary endpoint of overall survival.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 8:46 pm

GILD

Gilead Sciences announced that its Phase 3 TROPiCS-04 study for Trodelvy in metastatic urothelial cancer did not meet its primary endpoint of overall survival.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 8:45 pm

ONCT

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) has completed enrollment and initiated dosing for the fifth dose cohort in its Phase 1/2 study of ONCT-534 for treating metastatic castration-resistant prostate cancer. The Safety Review Committee approved the 600 mg dose after reviewing data from the 300 mg dose. Initial safety and efficacy data are expected in Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 8:45 pm

NXTC

NextCure, Inc. (NASDAQ:NXTC) will present Phase 1b data on the combination of NC410 and pembrolizumab at the ASCO 2024 Annual Meeting. The trial showed promising results in MSS/MSI-L CRC and ovarian cancer patients, with notable disease control rates.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 8:43 pm

TDG

Cerberus Capital Management has acquired Calspan's Hypersonic and Defense Test Systems business units from TransDigm Group. This acquisition aims to establish North Wind to advance U.S. hypersonic test capabilities.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 8:41 pm

GYRE

Gyre Therapeutics (NASDAQ:GYRE) has received approval from China's NMPA to evaluate its F230 tablets for the treatment of pulmonary arterial hypertension. This approval marks a significant milestone for the company in its development of anti-fibrotic therapeutics.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 8:37 pm

LRMR

Larimar Therapeutics has been selected by the FDA to participate in the START pilot program, which aims to accelerate the development of novel therapies for rare diseases. Their drug, Nomlabofusp, is being developed for Friedreich's Ataxia and has shown potential for clinical benefit. The program will enhance communication with the FDA to improve development efficiency, with a BLA submission targeted for the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 8:35 pm